Literature DB >> 17322576

The effects of royal jelly on autoimmunity in Graves' disease.

Cihangir Erem1, Orhan Deger, Ercüment Ovali, Yasam Barlak.   

Abstract

OBJECTIVE: Graves' disease is an organ-specific autoimmune disease with unknown etiology. TSHR Ab plays the most important role for the pathogenesis of Graves' disease. Recently, the role of cytokines for the pathogenesis of Graves' disease has been studied extensively. Royal jelly (RJ) is a creamy product secreted by young nurse worker bees (Apis mellifera), and it is synthesized in the hypopharyngeal and mandibular glands. RJ has been reported to have such pharmacological characteristics as antitumor, antibacterial, antihypercholesterolemic, antiallergic, antiinflammatory, and immunomodulatory properties. The major aim of the present study is to evaluate the effect of RJ on autoimmunity in peripheral lymphocyte culture and to establish the therapeutic doses. RESEARCH DESIGN AND METHODS: In the first phase, lymphocyte cell isolation from four voluntary healthy subjects was performed to find the effective concentration of RJ on immunity. Serial dilutions of the RJ were prepared (0-5 mg/mL). All isolated lymphocyte cells were treated with the above diluted samples. MTT test was carried out after incubation of 72 h. In the second phase, six patients with Graves' disease, newly diagnosed by clinical and laboratory methods and admitted to my hospital and untreated were identified. RJ samples of 0 and 4 mg/mL were incubated in a culture medium for 72 h with isolated lymphocytes obtained from the patients. After incubation, MTT test in lymphocyte cell culture, Th1 cytokines IFN-gamma, TNF-alpha, and IL-12, and Th2 cytokines IL-4 and IL-10 levels by the enzyme amplified sensitivity immunoassay (EASIA) method and TSHR Ab by the radioreceptor method were determined.
RESULTS: The concentration causing lymphocytes to proliferate was found to be 4 mg/mL by MTT test after incubation of 72 h in cell culture medium. Of the cytokines produced and secreted from lymphocytes, IFN-gamma increased, whereas, other cytokines decreased in RJ concentration of 4 mg/mL. Significant differences were found only for IFN-gamma and TNF-alpha. IL-4 concentrations were kept near the level of significancy. Of Th1/Th2 ratios, IFN-gamma/IL-4 and IFN-gamma/IL-10 ratios also exhibited significant differences between 0 and 4 mg/mL. RJ treatment in lymphocytes from patients with Graves' disease shifted the Th1/Th2 cytokine ratio to the side of Th1 cytokine. Therefore, RJ using the treatment and establishing a remission of Graves' disease may be effective as an antithyroid drug treatment. TSHR Ab levels of lymphocyte cell culture supernatants treated with RJ showed significant decreases. Also, the result may suggest that RJ may exert an effect similar to an antithyroid drug for decreasing TSHR Ab levels.
CONCLUSIONS: RJ may be effective as an immunomodulatory agent in Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17322576     DOI: 10.1385/ENDO:30:2:175

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  49 in total

Review 1.  Cellular immune responses in autoimmune thyroid disease.

Authors:  A P Weetman
Journal:  Clin Endocrinol (Oxf)       Date:  2004-10       Impact factor: 3.478

2.  A royal jelly as a new potential immunomodulator in rats and mice.

Authors:  L Sver; N Orsolić; Z Tadić; B Njari; I Valpotić; I Basić
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1996-01       Impact factor: 2.268

3.  IL-4 directs the development of Th2-like helper effectors.

Authors:  S L Swain; A D Weinberg; M English; G Huston
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

Review 4.  Cytokines and thyroid function.

Authors:  R A Ajjan; P F Watson; A P Weetman
Journal:  Adv Neuroimmunol       Date:  1996

5.  Differential immunosuppressive action of carbimazole and propylthiouracil.

Authors:  R Wilson; J H McKillop; C Pearson; A K Burnett; J A Thomson
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

6.  Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin.

Authors:  X P Pang; J M Hershman; M Chung; A E Pekary
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

Review 7.  Monoclonal antibodies to thyroid specific autoantigens.

Authors:  Takashi Akamizu
Journal:  Autoimmunity       Date:  2003 Sep-Nov       Impact factor: 2.815

8.  Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice.

Authors:  Yoshifumi Taniguchi; Keizo Kohno; Shin-ichiro Inoue; Satomi Koya-Miyata; Iwao Okamoto; Norie Arai; Kanso Iwaki; Masao Ikeda; Masashi Kurimoto
Journal:  Int Immunopharmacol       Date:  2003-09       Impact factor: 4.932

9.  Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves' disease.

Authors:  T Kocjan; B Wraber; A Kocijancic; S Hojker
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

10.  Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats.

Authors:  Katsu-hiko Tokunaga; Chie Yoshida; Kazu-michi Suzuki; Hiroe Maruyama; Yoshihiro Futamura; Yoko Araki; Satoshi Mishima
Journal:  Biol Pharm Bull       Date:  2004-02       Impact factor: 2.233

View more
  6 in total

1.  Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review.

Authors:  Elizabeth Ross; Khalid Abulaban; Elizabeth Kessler; Natoshia Cunningham
Journal:  Lupus       Date:  2022-04-20       Impact factor: 2.858

2.  The effect of royal jelly on the growth of breast cancer in mice.

Authors:  Shuang Zhang; Qiqi Shao; Haiyang Geng; Songkun Su
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

3.  Lifespan-extending effects of royal jelly and its related substances on the nematode Caenorhabditis elegans.

Authors:  Yoko Honda; Yasunori Fujita; Hiroe Maruyama; Yoko Araki; Kenji Ichihara; Akira Sato; Toshio Kojima; Masashi Tanaka; Yoshinori Nozawa; Masafumi Ito; Shuji Honda
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

4.  Effect of royal jelly on formalin induced-inflammation in rat hind paw.

Authors:  Ardeshir Arzi; Samaneh Olapour; Hamid Yaghooti; Neda Sistani Karampour
Journal:  Jundishapur J Nat Pharm Prod       Date:  2015-02-20

5.  Effects of royal jelly supplementation on regulatory T cells in children with SLE.

Authors:  Asmaa M Zahran; Khalid I Elsayh; Khaled Saad; Esraa M A Eloseily; Naglaa S Osman; Mohamd A Alblihed; Gamal Badr; Mohamed H Mahmoud
Journal:  Food Nutr Res       Date:  2016-11-24       Impact factor: 3.894

6.  Effect of Processed Honey and Royal Jelly on Cancer-Related Fatigue: A Double-Blind Randomized Clinical Trial.

Authors:  Bahram Mofid; Hossein Rezaeizadeh; Abdulkarim Termos; Afshin Rakhsha; Ahmad Rezazadeh Mafi; Taiebeh Taheripanah; Mehran Mirabzadeh Ardakani; Seyed Mohammad Esmaeil Taghavi; Seyyed Alireza Moravveji; Amir Shahram Yousefi Kashi
Journal:  Electron Physician       Date:  2016-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.